PDL-1 in non-small cell lung cancer (NSCLC): Association with molecular alterations and clinical outcome
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study found that squamous cell carcinoma has higher PDL-1 expression than adenocarcinoma. Integrating clinical, molecular, and immune data can improve PDL-1 biomarker prediction for lung cancer patients.
Area Of Science
- Oncology
- Immunology
- Genetics
Background
- Immune checkpoint inhibitors (ICI) targeting PDL-1 improve outcomes in lung adenocarcinoma.
- Understanding PDL-1's association with molecular alterations is crucial in non-small cell lung cancer (NSCLC).
Purpose Of The Study
- Correlate clinicopathological features with molecular phenotypes across PDL-1 subgroups.
- Analyze survival outcomes for NSCLC patients with PDL-1 expression >1%.
Main Methods
- Retrospective study of 100 NSCLC cases using next-generation sequencing (NGS) and PD-L1 SP263 clone.
- Analyzed PD-L1 expression, histology, and oncogenic mutations.
- Followed patients treated with immunotherapy (IO), targeted therapy (TT), or chemotherapy (CC) for overall survival (OS).
Main Results
- 51% of NSCLC cases showed positive PD-L1 expression.
- Squamous cell carcinoma (SCC) had higher PD-L1 expression than adenocarcinoma (AC) (P=0.005).
- EGFR mutations were exclusive to AC; KRAS mutations were more frequent in males (P=0.048).
- Median OS was 13 months for IO, 11 months for TT, and 7 months for CC.
Conclusions
- PD-L1 expression differs between NSCLC subtypes (SCC vs. AC).
- EGFR and KRAS mutations show distinct associations with NSCLC histology and sex.
- Immunotherapy and targeted therapy show improved survival over chemotherapy in PD-L1 positive NSCLC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.